covered individual may bring an action at law or equity for de novo review in the appropriate district court of the United States, which shall have jurisdiction over the action without regard to the amount in controversy, for lost wages and benefits, reinstatement, costs and attorney fees, compensatory damages, equitable or injunctive relief, or any other relief that the court considers appropriate.

''(B) JURY TRIAL.—An action brought under subparagraph (A) shall, upon the request of the covered individual, be tried by the court with a jury.

''(C) BURDEN OF PROOF.—The burdens of proof under subsection (e) of section 1221 shall apply to an allegation of a violation of subsection (a) of this section in an action brought under this paragraph in the same manner as those burdens of proof apply to an allegation of a prohibited personnel practice under such section 1221.

''(c) DEFINITIONS.—For purposes of this section—

''(1) the term 'covered individual', with respect to a Federal agency, means an employee of, former employee of, or applicant for employment with—

''(A) the agency; or

''(B) a contractor, subcontractor, grantee, subgrantee, or personal services contractor (as those terms are used in section 2409 of title 10 and section 4712 of title 41) of the agency; and

''(2) the term 'Federal agency' means an agency, office, or other establishment in the executive, legislative, or judicial branch of the Federal Government.''.

SA 4087. Mrs. FEINSTEIN submitted an amendment intended to be proposed to amendment SA 3867 submitted by Mr. REED and intended to be proposed to the bill H.R. 4350, to authorize appropriations for fiscal year 2022 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in subtitle G of title X, insert the following:

SEC. ___. ONE HEALTH CENTER OF EXCELLENCE.

(a) ESTABLISHMENT.—The Secretary of Health and Human Services (referred to in this section as the ''Secretary''), in consultation with the Commissioner of Food and Drugs, the Center for Veterinary Medicine, and the Office of the Chief Scientist of the Food and Drug Administration, not later than 1 year after the date of enactment of this Act, shall establish within the Food and Drug Administration a One Health Center of Excellence for purposes of strengthening inter- and intra-agency actions with respect to emerging public health threats, as described in subsection (b).

(b) ACTIVITIES.—The activities of the One Health Center of Excellence shall include the following:

(1) Developing programs and enhancing strategies to research, monitor, prevent, and respond to emerging public health threats, such as zoonotic disease outbreaks, as well as other biological, chemical, and radiological threats to public health.

(2) Supporting recruitment and training for personnel engaged in such research, monitoring, prevention, and response efforts.

(3) Conducting, promoting, and supporting research regarding public health threats.

(4) Improving public awareness and understanding of a One Health approach.

(5) Facilitating collaborative relationships among—

(A) relevant Federal agencies, such as the Department of Agriculture, the Department of the Interior, the Department of Defense, the Department of Commerce, the Department of Homeland Security, the United States Agency for International Development, the Food and Drug Administration, the Centers for Disease Control and Prevention, the National Institutes of Health, and the Environmental Protection Agency;

(B) Tribal Nations;

(C) State and local public health veterinarians and wildlife officials; and

(D) other experts, as determined by the Secretary.

(c) PUBLIC PROCESS.—The Secretary shall provide a period for public comment during the time that the One Health Center of Excellence is being implemented.

(d) ANNUAL REPORT.—Not later than January 1 of the year that begins 1 year after the One Health Center of Excellence is implemented, and annually thereafter, the Secretary shall publish on the website of the Food and Drug Administration a report on the activities of the One Health Center of Excellence and recommendations for Congress regarding additional legislation that may be needed to prevent and respond to emerging public health threats.

(e) AUTHORIZATION OF APPROPRIATIONS.—There are authorized to be appropriated such sums as may be necessary to carry out this section.

SA 4088. Mrs. FEINSTEIN (for herself and Mr. SCHATZ) submitted an amendment intended to be proposed to amendment SA 3867 submitted by Mr. REED and intended to be proposed to the bill H.R. 4350, to authorize appropriations for fiscal year 2022 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes; which was ordered to lie on the table; as follows:

At the end, add the following:

DIVISION E—CANNABIDIOL AND MARIHUANA RESEARCH EXPANSION

SEC. 5101. SHORT TITLE.

This division may be cited as the ''Cannabidiol and Marihuana Research Expansion Act''.

SEC. 5102. DEFINITIONS.

In this division—

(1) the term ''appropriately registered'' means that an individual or entity is registered under the Controlled Substances Act (21 U.S.C. 801 et seq.) to engage in the type of activity that is carried out by the individual or entity with respect to a controlled substance on the schedule that is applicable to cannabidiol or marihuana, as applicable;

(2) the term ''cannabidiol'' means—

(A) the substance, cannabidiol, as derived from marihuana that has a delta-9-tetrahydrocannabinol level that is greater than 0.3 percent; and

(B) the synthetic equivalent of the substance described in subparagraph (A);

(3) the terms ''controlled substance'', ''dispense'', ''distribute'', ''manufacture'', ''marihuana'', and ''practitioner'' have the meanings given such terms in section 102 of the Controlled Substances Act (21 U.S.C. 802), as amended by this division;

(4) the term ''covered institution of higher education'' means an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) that—

(A)(i) has highest or higher research activity, as defined by the Carnegie Classification of Institutions of Higher Education; or

(ii) is an accredited medical school or an accredited school of osteopathic medicine; and

(B) is appropriately registered under the Controlled Substances Act (21 U.S.C. 801 et seq.);

(5) the term ''drug'' has the meaning given the term in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(1));

(6) the term ''medical research for drug development'' means medical research that is—

(A) a preclinical study or clinical investigation conducted in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or otherwise permitted by the Department of Health and Human Services to determine the potential medical benefits of marihuana or cannabidiol as a drug; and

(B) conducted by a covered institution of higher education, practitioner, or manufacturer that is appropriately registered under the Controlled Substances Act (21 U.S.C. 801 et seq.); and

(7) the term ''State'' means any State of the United States, the District of Columbia, and any territory of the United States.

TITLE LI—REGISTRATIONS FOR MARIHUANA RESEARCH

SEC. 5121. MARIHUANA RESEARCH APPLICATIONS.

Section 303(f) of the Controlled Substances Act (21 U.S.C. 823(f)) is amended—

(1) by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively;

(2) by striking ''(f) The Attorney General'' and inserting ''(f)(1) The Attorney General'';

(3) by striking ''Registration applications'' and inserting the following:

''(2)(A) Registration applications'';

(4) by striking ''Article 7'' and inserting the following:

''(3) Article 7''; and

(5) by inserting after paragraph (2)(A), as so designated, the following:

''(B)(i) The Attorney General shall register a practitioner to conduct research with marihuana if—

''(I) the applicant's research protocol—

''(aa) has been reviewed and allowed—

''(AA) by the Secretary of Health and Human Services under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i));

''(BB) by the National Institutes of Health or another Federal agency that funds scientific research; or

''(CC) pursuant to sections 1301.18 and 1301.32 of title 21, Code of Federal Regulations, or any successors thereto; and

''(II) the applicant has demonstrated to the Attorney General that there are effective procedures in place to adequately safeguard against diversion of the controlled substance for legitimate medical or scientific use pursuant to section 5125 of the Cannabidiol and Marihuana Research Expansion Act, including demonstrating that the security measures are adequate for storing the quantity of marihuana the applicant would be authorized to possess.

''(ii) The Attorney General may deny an application for registration under this subparagraph only if the Attorney General determines that the issuance of the registration would be inconsistent with the public interest. In determining the public interest, the Attorney General shall consider the factors listed in—

''(I) subparagraphs (B) through (E) of paragraph (1); and